New York, NY -- (SBWIRE) -- 01/28/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Mitsubishi UFJ Financial Group Inc (ADR) (NYSE:MTU), Vical Incorporated (NASDAQ:VICL), CytRx Corporation (NASDAQ:CYTR), PDL BioPharma Inc (NASDAQ:PDLI)
Mitsubishi UFJ Financial Group Inc (ADR) (NYSE:MTU) showed a volume of 2.03 million shares by the end of last trade whereas the average volume of the stock remained 1.50 million shares. The stock opened the session at $6.23 but then moved to $6.18. At that price, the stock showed a negative performance of -2.06%. Mitsubishi UFJ Financial Group, Inc. is a Japan-based company mainly engaged in the banking business. The Company is also involved in trust banking business, security business, credit card business, leasing business and other businesses.
Will MTU Get Buyers Even After The Recent Rally? Find Out Here
Vical Incorporated (NASDAQ:VICL) opened the session at $1.50 and closed the session at $1.38. The stock showed a negative performance of -7.38% in previous trading session. Traded with volume of 2.03 million shares in the prior session and the average volume of the stock remained 2.29 million shares. Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases.
Has VICL Found The Bottom And Ready To Gain Momentum? Find Out Here
CytRx Corporation (NASDAQ:CYTR) opened the session at $7.30 and closed the session at $6.80. The stock showed a negative performance of -6.46% in previous trading session. Traded with volume of 2.02 million shares in the prior session and the average volume of the stock remained 6.40 million shares. The beta of the stock remained 1.33. CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company's oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib.
Why Should Investors Buy CYTR After the Recent Fall? Just Go Here and Find Out
PDL BioPharma Inc (NASDAQ:PDLI) the stock decreased -1.00% and finished the session at $8.94. Traded with volume of 2.01 million shares in the prior session and the average volume of the stock remained 2.12 million shares. The beta of the stock remained 0.60. PDL BioPharma, Inc. (PDL) is a is a biotech company. PDL is engaged in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies.
Will PDLI Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)